1 / 23

A Double-Blind, Randomized, Placebo-Controlled Study of Calcium Glycerophosphate Dietary Supplement in Patients with Ove

Risk Factors for Urinary Incontinence. Predisposing FactorsGenderGeneticsRaceCultureNeurologyAnatomyCollagen Status. Promoting FactorsBowel DysfunctionDietary IrritantsActivity LevelObesityMenopauseInfectionMedicationPulmonary StatusPsychiatric Status. Inciting FactorsChildbirthSurgeryPelvic Nerve DamageRadiation.

taran
Download Presentation

A Double-Blind, Randomized, Placebo-Controlled Study of Calcium Glycerophosphate Dietary Supplement in Patients with Ove

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. A Double-Blind, Randomized, Placebo-Controlled Study of Calcium Glycerophosphate Dietary Supplement in Patients with Overactive Bladder Michael J. Kennelly, MD Robbin Clark, RN Marvin S. Medow, PhD McKay Department of Urology Carolinas Medical Center Charlotte, NC

    2. Risk Factors for Urinary Incontinence

    3. Dietary Irritants Alcoholic beverages Caffeinated products Citrus juice and fruits Tomatoes and tomato-based products Highly spicy foods Artificial sweeteners

    4. Purpose To evaluate the efficacy of calcium glycerophospate dietary supplement (Prelief®) in patients with overactive bladder (OAB) To evaluate patient acceptance and satisfaction with Prelief®

    5. Study Design Prospective, randomized, single-center, double-blind, placebo-controlled 3 weeks study duration on Prelief® or placebo Two study tablets were taken TID daily with meals Placebo was identical to the active product with respect to size, color, and odor IRB approved

    6. Study Design Double-blind Placebo controlled Single center 60 patients enrolled 4 week study with 3 weeks of treatment on Prelief® or placebo 2 tablets TID with meals Placebo identical to Prelief® in size, shape, color. IRB approved

    7. Inclusion Criteria > 18 years of age with OAB OAB defined as: Urinary Frequency > 8 voids on average/24 hours Urgency Urge Incontinence > 1 UUI episode/24 hours confirmed on micturition chart Stable OAB medications continued throughout the study

    8. Exclusion Criteria Mixed incontinence with 1° symptom is SUI Acute UTI in run-in period Known treatable GU condition UTI, prostatitis, BOO, TCCA, bladder stone, prostate cancer, radiation therapy to pelvis Uninvestigated hematuria Indwelling foley, SPT, or on CIC Known allergy or hypersensitivity to Prelief®

    9. Analysis of Efficacy Data Objective Assessment 3-day voiding diary Mean # voids/24 hr Mean # nocturia/24 hr Mean # incontinent episodes/ 24 hr Mean # of pads used/ 24 hr Subjective Assessment Perception degree of Urgency Incontinence Impact Questionnaire (IIQ) Satisfaction scale Questionnaires

    10. Demographics

    11. Demographics

    12. Mean Reduction in Frequency and Nocturia at 3 weeks

    13. Mean Reduction in Urge Incontinent Episodes and Number of Pads Used

    14. Patient Perception of Urgency at 3 Weeks I was usually not able to hold urine at all I was usually able to hold urine until I reached a toilet (without leaking) if I went there immediately I was usually able to finish what I was doing before going to the toilet (without leaking)

    15. Patient Satisfaction at 3 weeks How well has this therapy worked for you OAB? Not at all Poor Fair Good Very Good Excellent

    16. Patient Satisfaction at 3 Weeks How pleased have you been with this therapy for you OAB? Extremely displeased Very displeased A bit displeased Pleased Very pleased Extremely pleased

    17. Patient Satisfaction at 3 weeks How much have you benefited from this therapy for your OAB problem? Not at all A little bit Some A lot

    18. Patient Satisfaction at 3 weeks Mean values for Worked, Pleased, & Benefited

    19. Mean Reduction in IIQ-7 Questions

    20. IIQ-7 Short Form at 3 weeks

    21. IIQ Results at 3 weeks Mean reduction in IIQ-7 Total Score Placebo 9.16 Prelief® 17.33 Most improvements in Ability to socialize Quantity of sleep Ability to go places Ability to wear clothes Performance of exercises Ability to attend entertainment

    22. Conclusions Prelief® did not show any significant improvements in voiding diary data. Trend in reduction of urinary frequency & nocturia Patients noted significant QOL improvements on Prelief® Worked p= 0.026 Pleased p=0.034 Benefited p=0.0143

    23. Conclusions Mechanism by which spicy and acidic foods exacerbate OAB symptoms is unknown Theory is sensitization of sensory afferent nerves of urothelium Many OAB patients are food sensitive and can identify bladder irritants Consequently, if OAB patients are acid food sensitive, Prelief® is safe and efficacious in subjective improvement of symptoms and QOL

    24. A Double-Blind, Randomized, Placebo-Controlled Study of Calcium Glycerophosphate Dietary Supplement in Patients with Overactive Bladder Realize that many OAB patients are food sensitive and can identify bladder irritants. Council your OAB patients on dietary modification. Understand the mechanism by which spicy and acidic foods exacerbate OAB symptoms is unknown. Theory is sensitization of sensory afferent nerves of urothelium. Do not use calcium glycerophosphate to dramatically change objective voiding diary data (frequency, urgency, or urge incontinence). If OAB patients want a non-Rx alternative to improve subjective symptoms and quality of life, consider calcium glycerophosphate dietary supplement for those OAB patients who are acid food sensitive.

More Related